Option Found for Retreatment of Chronic Hep C Infection
THURSDAY, Nov. 15, 2018 -- Combined treatment with glecaprevir and pibrentasvir (G/P) is highly effective in treating chronic hepatitis C virus (HCV) genotype-1 infections that failed to respond to direct-acting antiviral therapy, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 15, 2018 Category: Pharmaceuticals Source Type: news
Hepatitis C Treatment Options: 5 Direct Questions
An HCV-infected patient who still injects drugs wants to start direct-acting antiviral therapy. What do guidelines recommend? (Source: ConsultantLive)
Source: ConsultantLive - November 14, 2018 Category: Internal Medicine Authors: Andrew Bowser Tags: Hepatitis C Source Type: news
HCV-Infected Kidney Waitlist Patients: Treat Now or Later? HCV-Infected Kidney Waitlist Patients: Treat Now or Later?
Which factors should be considered in the decision to initiate early or deferred direct-acting antiviral therapy among HCV-positive waitlisted patients?American Journal of Transplantation (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 1, 2018 Category: Surgery Tags: Nephrology Journal Article Source Type: news
Direct-acting antiviral therapy for hepatitis C saves costs in Italy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2018 Category: Drugs & Pharmacology Source Type: news
Eight Weeks of Antiviral Therapy for Recent HCV Infection Eight Weeks of Antiviral Therapy for Recent HCV Infection
Is an 8-week therapy of paritaprevir/ritonavir/ombitasvir and dasabuvir + ribavirin as effective as the standard 12-week regimen in individuals with recent HCV infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Preemptive DAAs for HCV+ Donor Livers Found Cost Effective
(MedPage Today) -- Direct-acting antiviral therapy in seronegative liver recipients could shorten transplant waiting lists (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 24, 2018 Category: Gastroenterology Source Type: news
Recurrence of HCC Following Direct-acting Antiviral Therapy Recurrence of HCC Following Direct-acting Antiviral Therapy
Might direct-acting antivirals increase risk and aggressiveness of hepatocellular carcinoma recurrence? This review aimed to characterize HCC recurrence patterns after DAA therapy.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
Treatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2018 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
Hep C Expert Interview: Gregory T. Everson, MD
Renowned transplant expert Gregory T. Everson, MD, talked with Patient Care about sensitive issues surrounding liver transplant in the era of direct-acting antiviral therapy. (Source: ConsultantLive)
Source: ConsultantLive - August 1, 2018 Category: Internal Medicine Authors: Andrew D. Bowser Tags: Hepatitis C Source Type: news
